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Introduction
Glucose homeostasis and insulin metabolism are com-
plex in patients with chronic renal failure. Though
most uremic patients are insulin-resistant with associ-
ated glucose intolerance, hypoglycemia occurs in some
patients undergoing hemodialysis. Both impaired
insulin degradation and reduced renal gluconeogenesis
in uremic patients increase the risk of hypoglycemia.1,2
Drug-induced hypoglycemia is common in uremic
patients. But other factors, including sepsis, alcohol
consumption, concomitant liver disease, congestive
heart failure and malnutrition, possibly trigger the
occurrence of hypoglycemia.
Propoxyphene is an opioid analgesic chemically sim-
ilar to methadone, which is used for analgesia. We
describe a patient undergoing hemodialysis, who devel-
oped recurrent hypoglycemia with presentation of cold
sweats and disturbed consciousness during treatment
with propoxyphene. In uremia, neuroglycopenic man-
ifestations predominate because of autonomic nervous
system dysfunction and possibly lack of immediate
release of counter-regulatory hormones.3 Therefore,
in uremic patients who suffer from change of conscious-
ness, the differential diagnosis should include hypo-
glycemia induced by prescribed medications, especially
propoxyphene.
Case Report
An 82-year-old woman with diabetic nephropathy in
end-stage renal disease undergoing long-term mainte-
nance hemodialysis was admitted to our hospital for
permanent catheter (PermCath, Arrow Cannon™ II
Plus; Quinton Instrument Co., Seattle, WA, USA)-
related infection. Her usual medications included
isosorbide-5-mononitrate (20 mg daily), carvedilol
(6.25 mg twice daily), hydralazine (10 mg twice daily),
nifedipine (20 mg twice daily), and estazolam (2 mg
daily). Her blood sugar was controlled by diet, and
she had not used any oral antidiabetic drug or insulin
for 2 years. The PermCath was removed, and she was
treated with antibiotics. A temporary femoral venous
catheter was inserted for hemodialysis. The patient
complained of intolerable pain over the insertion site
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and was irresponsive to acetaminophen. Therefore,
Depain X®, 1 tablet 4 times daily, was prescribed for pain
relief. Each Depain X® tablet contains propoxyphene
65 mg and acetaminophen 650 mg.
Five days later, the patient presented with cold
sweats and drowsy consciousness in the early morning,
with fasting blood glucose of 2.28mmol/L. The symp-
toms were relieved after intravenous administration of
50% glucose solution. Meanwhile, plasma immunore-
active insulin (IRI) was elevated to 52.45 pmol/L.
Maintenance glucose solution was prescribed after a
bolus of 50% glucose solution. Fasting plasma glucose
under continuous infusion of 10% glucose solution
ranged from 3.17mmol/L to 5.56mmol/L. However,
fasting hypoglycemia recurred due to withholding glu-
cose solution treatment by the presentation of agitation,
cold sweating and drowsy consciousness 10 days after
the first episode. A blood glucose concentration of
2 mmol/L and high IRI level of 139.2 pmol/L as
well as C-peptide level of 3.51 nmol/L were noted
(Figure 1). These findings were consistent with
hyperinsulinemic hypoglycemia, with plasma insulin
concentration > 43 pmol/L and plasma C-peptide
> 0.2 nmol/L when plasma glucose concentration
was < 2.5 mmol/L in the fasting state with symptoms.
Abdominal magnetic resonance imaging (MRI)
study did not reveal insulinoma or other pancreatic
lesions. Cortisol level during hypoglycemia was
563.04 nmol/L (reference range, 138–690 nmol/L).
The patient was afebrile, with normal white blood cell
counts of 9,400/mm3 and C-reactive protein of
9.6 mg/L (reference range, < 10 mg/L). She was fed
with normal adult solid diet by mouth thrice a day, and
her caloric intake was adequate, with approximately
36 kcal per kilogram per day. She had no alcohol 
consumption or concomitant liver disease with serum
alanine aminotransferase of 14 U/L, aspartate amino-
transferase of 19U/L and total bilirubin of 0.3mg/dL.
Hence, drug-related hypoglycemia was suspected.
Depain X® was discontinued 4 days after the second
episode of hypoglycemia. Upon discontinuation of
Depain X®, blood glucose levels returned to a stable
range of 6.11–8.94 mmol/L and the symptoms of
hypoglycemia resolved. The follow-up IRI levels were
reduced to 20.23pmol/L and 19.62pmol/L with fast-
ing plasma glucose concentrations of 6.39 mmol/L
and 6.67 mmol/L, respectively (Figure 1). Thereafter,
no further episodes of hypoglycemia occurred.
Discussion
The kidney plays an important role in glucose homeo-
stasis and insulin metabolism. Recent findings have
indicated that the kidney, in addition to the liver, makes
a significant contribution to gluconeogenesis under
various conditions. Renal gluconeogenesis accounts for
about 40–50% of systemic glucose release in the postab-
sorptive state of humans. The pathogenesis of sponta-
neous hypoglycemia with unknown causes in uremia
is complex and associated with reduced renal gluco-
neogenesis, impaired renal insulin degradation and
clearance.1–4 Hypoglycemia in chronic renal failure
patients has various causes and is frequently related to
the prescribed medications. Drugs known to induce
hypoglycemia include insulin, oral antidiabetic drugs,
salicylates,5 sulfonamide,6 disopyramide7 and propoxy-
phene.8–10 Other triggering events such as alcohol con-
sumption, sepsis, chronic malnutrition, acute caloric
deprivation, concomitant liver disease, congestive heart
failure, and associated endocrine deficiency were not
observed in our case.3
It is important to obtain a thorough medication
history in uremic patients with hypoglycemia. Side
effects of propoxyphene such as dizziness, vomiting,
constipation, stomach upset, skin rash, headache and
drowsiness are common, but hypoglycemia is unusual.
The first case of propoxyphene-induced hypoglycemia
was reported by Wiederholt et al.8 They described a
57-year-old woman with metastatic cervical cancer
and renal failure who experienced recurrent fasting
hypoglycemia during treatment with propoxyphene.
The hypoglycemia episode with manifestation of focal
reversible neurologic disturbance could not be explained
by any focal alterations of cerebral vasculature at
autopsy. Almirall et al9 reported that a 36-year-old
man with ankylosing spondylitis, amyloidosis and
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Figure 1. Fasting blood glucose profile (white circles) shows 2
hypoglycemic episodes with elevated insulin levels (black trian-
gles) during administration of Depain X® from August 19, 2006 
to September 8, 2006. Blood sugar returned to normal range on
September 13, 2006 after withdrawal of propoxyphene for 5 days.
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chronic renal failure on maintenance hemodialysis
developed severe hypoglycemia while being treated
with propoxyphene. Another case, reported by Shah
et al,10 was that of a 54-year-old man with chronic
renal failure who had recurrent episodes of hypo-
glycemia during treatment with propoxyphene. Inap-
propriately elevated plasma insulin, serum C-peptide,
and proinsulin levels were also noted. These cases and
our patient did not experience any episode of hypo-
glycemia after withdrawal of propoxyphene.
The temporal association between propoxyphene
and hypoglycemia, and the recovery from hypoglycemia
upon discontinuation of propoxyphene strongly impli-
cated propoxyphene-induced hypoglycemia in our case.
Hyperinsulinemia occurring during treatment and
resolving after withdrawal of propoxyphene also indi-
cated the possible potentiation effect of insulin release.
The subsequent resolution of hyperinsulinemia and neg-
ative abdominal MRI study further excluded the pos-
sibility of insulinoma. So far, the true mechanism of
propoxyphene-induced hypoglycemia is still obscure.
In conclusion, hypoglycemia is a severe life-
threatening complication and should be suspected in
any uremic patient with cold sweats, agitation and
depressed consciousness. This case report draws the
attention to the possibility that propoxyphene might
be responsible for hypoglycemia, especially in uremic
patients.
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